« Previous Next » Contraception
Volume 73, Issue 5 , Pages 440-442 , May 2006

Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: Evidence-based clinical science should guide FDA decision making about product labeling

Lee P. Shulman
- Department of Obstetrics and Gynecology, Division of Reproductive Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
- Corresponding author.
Louise H. Bateman
- Houston, TX, USA
Mitchell D. Creinin
- Department of Obstetrics, Gynecology and Reproductive Science, Magee Women's Hospital, University of Pittsburgh, Pittsburgh, PA 15213, USA
Vanessa E. Cullins
- Planned Parenthood Federation of America, New York, NY 10001, USA
Lee Lee Doyle
- University of Arkansas for Medical Science, Little Rock, AR 72205-7199, USA
Emily Godfrey
- Department of Family Medicine, University of Illinois, Chicago, Chicago, IL 60612, USA
Patricia Murphy
- University of Utah School of Nursing, Salt Lake City, UT 84112, USA
Pablo Rodriguez
- Planned Parenthood of Rhode Island, Warwick, RI 02889, USA
Scott J. Spear
- University Health Services, University of Wisconsin-Madison, Madison, WI 53726, USA
Felicia H. Stewart
- Department of Obstetrics, Gynecology and Reproductive Sciences, Bixby UCSF Center for Reproductive Health Research and Policy, University of California, San Francisco, San Francisco, CA 94143-1744, USA
Michael A. Thomas
- Medical Center for Reproductive Health, University of Cincinnati, Cincinnati, OH 45219, USA
Carolyn L. Westhoff
- Columbia University Medical Center, New York, NY 10032, USA
Sandra Worthington
- Planned Parenthood Federation of America Nurse Practitioner Program, Philadelphia, PA 19102, USA

Received 16 January 2006 ,Revised 17 January 2006 ,Accepted 18 January 2006.

References

Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol. 2005;105:1114–1118
- MEDLINE
- CrossRef
Kaunitz AM. Depo-Provera's black box: time to reconsider?. Contraception. 2005;72(3):165–167
Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005;18:797–804
- MEDLINE
- CrossRef
Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf. 2004;27:1001–1018
- MEDLINE
- CrossRef
van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinyl estradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168–174
Chaker AM. Doctors back off birth-control patch after FDA warning on excessive hormones, some stop prescribing popular method weighing choices. Wall St J. 2005;